AdvaMed® submitted a letter to CMS’s RFI on Medicare regarding ways to strengthen the Medicare Advantage program to align with the Vision for Medicare and CMS’ Strategic Pillars.
AdvaMed® submitted comments to CMS the CY 2023 End Stage Renal Disease (ESRD) Prospective Payment System.
AdvaMed® submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.
AdvaMed® submitted comments to CMS on the Fiscal Year 2023 Hospital Inpatient Prospective Payment System proposed rule.
AdvaMed® submitted comments to the Center for Medicare and Medicaid Services (CMS) on its Radiation Oncology (RO) Model proposed rule proposing to indefinitely delay the start date of the RO…
AdvaMed® submitted a letter regarding proposed local coverage determinations entitled “Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcer.”
AdvaMed® urged CDC to recognize the critical role evidence-based and FDA-approved/cleared devices can and should play in improving pain management and reducing opioid-related harms.
During two listening sessions, AdvaMed® provided responses to a set of questions posed by CMS on the parameters for a new TCET program, including the types of guidance provided by…
AdvaMed® submitted a response to a Department of Health and Human Services (HHS) Office of the National Coordinator for Health Information Technology (ONC) Request for Information (RFI) on electronic prior…
AdvaMed® submitted a response to a U.S. House of Representatives Healthy Futures Task Force, Subcommittee on Treatments (Subcommittee on Treatments) Request for Information (RFI) on information to help foster patient…